Ceruvia Lifesciences, Inc.

11:15 AM - 11:30 AM (PDT), Tuesday, June 14, 2022
Ceruvia Lifesciences researches, develops, and manufactures neurotransformational medicines to address challenging hard-to-treat disorders, including alcohol use disorder (AUD), migraine, cluster headache and obsessive compulsive disorder (OCD).
Ceruvia currently has two molecules in development.
SYNP-101 is a synthetic psilocybin which, given the results of a phase 2a trial by Prof. Michael Bogenschutz at NYU, is poised to begin a phase 2b trial in AUD this year. Also planned for this year are phase 2a trials in both OCD and migraine.
NYPRG101 (aka BOL-148), a non-hallucinogenic congener of LSD, is set to enter the clinic with a phase 1 SAD trial starting in early Q3 this year. Once this trial is up and running, planning for a Phase 2a trial in migraine will commence, targeting a start date in 1H/2023.
Company Type:
Privately Funded Company
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
SYNP-101 (synthetic psilocybin)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2